 NEW YORK, Jan. 04, 2021 GLOBE NEWSWIRE -- Renalytix AI plc LSE: RENX NASDAQ: RNLX, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be presenting at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference. 